Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13940030 | 1.00 | ACHE (0.65) | ACHERELACA12CA1CA2 | |
| SCHEMBL12730666 | 0.92 | ACHE (0.56) | ACHERELACA12CA1CA2 | |
| SCHEMBL16321127 | 0.92 | ACHE (0.56) | ACHERELACA12CA1CA2 | |
| SCHEMBL1975657 | 0.91 | CA1 (0.58) | ACHECA12CA1CA2CA7 | |
| SCHEMBL11872451 | 0.87 | ACHE (0.65) | ACHERELACA12CA1CA2 | |
| SCHEMBL21880569 | 0.84 | ESR2 (0.52) | ACHECA12CA1CA2CA7 | |
| SCHEMBL13939468 | 0.83 | ACHE (0.46) | ACHERELAALDH1A1TDP1L3MBTL1 | |
| SCHEMBL11588689 | 0.83 | TSHR (0.55) | ACHECA1CA2CA7CA9 | |
| SCHEMBL11527250 | 0.83 | TSHR (0.55) | ACHECA1CA2CA7CA9 | |
| SCHEMBL121800 | 0.83 | CA4 (0.54) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182135-A1 | Amino modifiers | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20090182135-A1 | Amino modifiers | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20090182135-A1 | Amino modifiers | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182135-A1 | Amino modifiers | BCAT2, AADAT, BCAT1 | ACHE 1503/4885RELA 1443/4885CA12 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.